BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wendel S, Fachini R, Fontão-Wendel RCL, Mello R, Velasquez CV, Machado RRG, Brito MA, Amaral M, Soares CP, Achkar R, Scuracchio P, Miyaji SC, Erdens MS, Durigon EL. Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be? Transfusion 2021. [PMID: 34674284 DOI: 10.1111/trf.16714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Pobegalova OE, Kozmovskaya NV, Monakhov NE, Kholodnaya AN, Danilenko DM, Antonova TV, Lioznov AD. Time-related changes in the titer of virus neutralizing antibodies against SARS-CoV-2 after COVID-19 in patients with HIV infection. VIČ-infekc immunosupr 2023;14:59-66. [DOI: 10.22328/2077-9828-2022-14-4-59-66] [Reference Citation Analysis]
2 Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.02.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]